gabapentin and Edema-Proteinuria-Hypertension Gestosis studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

Excerpt	Relevance	Reference
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	8.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
" We examined the risk of major congenital malformations and cardiac defects associated with gabapentin exposure during the first trimester (T1), and the risk of preeclampsia (PE), preterm birth (PTB), small for gestational age (SGA), and neonatal intensive care unit admission (NICUa) associated with gabapentin exposure early, late, or both early and late in pregnancy."	7.96	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E, 2020)
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	4.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
" We examined the risk of major congenital malformations and cardiac defects associated with gabapentin exposure during the first trimester (T1), and the risk of preeclampsia (PE), preterm birth (PTB), small for gestational age (SGA), and neonatal intensive care unit admission (NICUa) associated with gabapentin exposure early, late, or both early and late in pregnancy."	3.96	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E, 2020)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Narcotic Utilization

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors	Studies
Patorno, E	1
Hernandez-Diaz, S	1
Huybrechts, KF	1
Desai, RJ	1
Cohen, JM	1
Mogun, H	1
Bateman, BT	1
Guttuso, T	1
Shaman, M	1
Thornburg, LL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119]	Phase 3	1,494 participants (Actual)	Interventional	2017-10-04	Terminated (stopped due to Lack of Funding/ Resident in charge graduated)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)

Reviews

Other Studies

1 other study available for gabapentin and Edema-Proteinuria-Hypertension Gestosis

Intervention	MME (Mean)
Alternate Management	33.3
Control	47.2